We provide you with 20 years of free, institutional-grade data for DMTK stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of DMTK. Explore the full financial landscape of DMTK stock.
| Reported Date | CIK | Ticker | Type |
|---|
DermTech, Inc(NASDAQ:DMTK) 
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and t...
Website: http://www.dermtech.com
Founded: 1996
CEO / Founder: John Dobak, M.D.
Sector: Healthcare
Industry: Diagnostics & Research
Share this website to your friends
The information provided in this report about DMTK stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.